Revolution Medicines (NASDAQ:RVMD) Stock: Insider Stephen Michael Kelsey Sells 27,160 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) insider Stephen Kelsey sold 27,160 shares of the company’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $167.86, for a total value of $4,559,077.60. Following the completion of the sale, the insider owned 286,307 shares of the company’s stock, valued at approximately $48,059,493.02. The trade was a 8.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Stephen Michael Kelsey also recently made the following trade(s):

  • On Wednesday, September 16th, Stephen Kelsey sold 5,569 shares of Revolution Medicines stock. The stock was sold at an average price of $199.24, for a total transaction of $1,109,567.56.
  • On Friday, September 11th, Stephen Kelsey sold 92,531 shares of Revolution Medicines stock. The stock was sold at an average price of $202.36, for a total value of $18,724,573.16.

Revolution Medicines Trading Down 0.2%

Shares of NASDAQ:RVMD opened at $159.43 on Friday. The firm has a market capitalization of $34.48 billion, a price-to-earnings ratio of -17.50 and a beta of 1.44. Revolution Medicines, Inc. has a 1 year low of $69.50 and a 1 year high of $224.31. The business’s 50 day moving average price is $190.87 and its 200-day moving average price is $160.71. The company has a debt-to-equity ratio of 0.44, a current ratio of 8.36 and a quick ratio of 8.34.

Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The company had revenue of $197.56 million for the quarter, compared to analysts’ expectations of $25.58 million. During the same period in the prior year, the company posted ($1.61) EPS. On average, equities research analysts forecast that Revolution Medicines, Inc. will post -7.41 earnings per share for the current fiscal year.

Institutional Trading of Revolution Medicines

Several institutional investors and hedge funds have recently modified their holdings of the company. Burkett Financial Services LLC purchased a new stake in Revolution Medicines during the third quarter valued at approximately $27,000. Contravisory Investment Management Inc. purchased a new stake in Revolution Medicines during the second quarter worth approximately $32,000. Johnson Financial Group Inc. acquired a new position in Revolution Medicines in the second quarter valued at $37,000. Silvant Capital Management LLC purchased a new stake in shares of Revolution Medicines in the second quarter valued at $41,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of Revolution Medicines during the 2nd quarter worth about $41,000. 94.34% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. TD Cowen boosted their price target on shares of Revolution Medicines from $250.00 to $270.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Wedbush increased their price target on Revolution Medicines from $201.00 to $225.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. Royal Bank Of Canada upped their price objective on Revolution Medicines from $260.00 to $321.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Piper Sandler increased their target price on shares of Revolution Medicines from $210.00 to $222.00 and gave the stock an “overweight” rating in a research report on Thursday, November 5th. Finally, Truist Financial reissued a “buy” rating and set a $261.00 price objective (up from $241.00) on shares of Revolution Medicines in a report on Thursday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Revolution Medicines has an average rating of “Moderate Buy” and a consensus target price of $262.75.

Read Our Latest Analysis on RVMD

Revolution Medicines Company Profile

(Get Free Report)

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

Featured Articles

Insider Buying and Selling by Quarter for Revolution Medicines (NASDAQ:RVMD)

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.